P3 Health Partners Raises 2026 EBITDA Outlook to $80M-$110M After Q2 Beat
PIII has more than doubled off its 52-week low of $1.52 on light trading volume (0.2× avg).
Summary
P3 Health Partners delivered a strong Q2, with revenue of $386M beating the $377.95M consensus and net income hitting $15.7M. Adjusted EBITDA swung to a $54M profit from a loss a year ago, driven by structural improvements in contracts, network, and operating model. The company raised its full-year 2026 adjusted EBITDA guidance to $80M-$110M, well above prior expectations, and set revenue guidance at $1.5B-$1.6B. This follows the company's first-ever positive net income and EBITDA in Q1, signaling a sustained turnaround. The stock is trading near its 52-week high of $16.89, reflecting growing confidence in the operational overhaul. Key drivers include a 15% YoY increase in per-member capitated revenue and favorable payer settlements. With a market cap under $100M, the magnitude of the guidance raise is highly material.
At the time of this announcement, PIII was trading at $16.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93M. The 52-week trading range was $1.52 to $16.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.